Parnax Lab Limited
BSE: PARNAXLAB
Prev Close
126
Open Price
126.45
Volume
2,098
Today Low / High
120.25 / 126.5
52 WK Low / High
81 / 178
Range
116 - 129
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 122.5, reflecting a change of -3.5 (-2.77778%). The expected target range on the BSE is 116 - 129. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Parnax Lab Limited Graph
Parnax Lab Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Parnax Lab Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 122.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 122.50 | 123.73 | 111.35 - 136.10 |
| 124.95 | 99.96 - 149.94 | ||
| 126.18 | 88.32 - 164.03 | ||
| Bearish Scenario | 122.50 | 121.28 | 109.15 - 133.40 |
| 120.05 | 96.04 - 144.06 | ||
| 118.83 | 83.18 - 154.47 |
Overview of Parnax Lab Limited
ISIN
INE383L01019
Industry
Medical - Pharmaceuticals
Vol.Avg
5,376
Market Cap
1,406,986,000
Last Dividend
0
Official Website
IPO Date
DCF Diff
221.44
DCF
-95
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 187.74 Cr | 96.00 Cr | 91.74 Cr | 0.4886 | 0.00 Cr | 0.00 Cr | 19.39 Cr | 11.52 Cr | 10.09 | 28.44 Cr | 0.0614 |
| 2024-03-31 | 188.71 Cr | 163.97 Cr | 24.74 Cr | 0.1311 | 0.58 Cr | 4.83 Cr | 16.68 Cr | 9.61 Cr | 8.37 | 24.36 Cr | 0.0509 |
| 2023-03-31 | 167.61 Cr | 116.34 Cr | 51.27 Cr | 0.3059 | 0.21 Cr | 4.56 Cr | 16.75 Cr | 8.62 Cr | 7.79 | 23.71 Cr | 0.0514 |
| 2022-03-31 | 163.03 Cr | 115.02 Cr | 48.02 Cr | 0.2945 | 0.28 Cr | 4.16 Cr | 17.63 Cr | 8.24 Cr | 9.68 | 23.30 Cr | 0.0506 |
| 2021-03-31 | 90.06 Cr | 60.51 Cr | 29.55 Cr | 0.3281 | 0.04 Cr | 3.63 Cr | 4.99 Cr | -0.36 Cr | -0.43 | 10.06 Cr | -0.0040 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.55 Cr | 189.82 Cr | 106.58 Cr | 83.0992 Cr | 69.53 Cr | 68.98 Cr | 25.77 Cr | 109.44 Cr | 0.00 Cr | 0.00 Cr | 0.16 Cr | 74.3339 Cr |
| 2024-03-31 | 0.46 Cr | 188.77 Cr | 117.07 Cr | 71.5727 Cr | 80.64 Cr | 80.18 Cr | 29.93 Cr | 111.70 Cr | 0.06 Cr | 0.00 Cr | -0.58 Cr | 81.8312 Cr |
| 2023-03-31 | 1.28 Cr | 145.07 Cr | 82.81 Cr | 62.1541 Cr | 54.72 Cr | 53.44 Cr | 21.69 Cr | 83.03 Cr | 0.35 Cr | 0.00 Cr | 0.16 Cr | 63.0417 Cr |
| 2022-03-31 | 4.36 Cr | 153.46 Cr | 105.19 Cr | 48.1864 Cr | 69.07 Cr | 64.71 Cr | 19.93 Cr | 75.20 Cr | 0.00 Cr | 0.00 Cr | 0.22 Cr | 80.9772 Cr |
| 2021-03-31 | 0.18 Cr | 106.26 Cr | 73.64 Cr | 32.5437 Cr | 58.90 Cr | 58.72 Cr | 10.79 Cr | 64.43 Cr | 0.10 Cr | 0.00 Cr | 0.22 Cr | 54.3740 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32.3015 Cr | -16.3941 Cr | -15.8153 Cr | 13.7235 Cr | 0.0921 Cr | 0.5499 Cr | -18.5780 Cr | 15.6742 Cr | -10.4246 Cr | 0.0000 Cr | 4.1584 Cr |
| 2024-03-31 | 15.8770 Cr | -31.5159 Cr | 14.8172 Cr | -16.5380 Cr | -0.8217 Cr | 0.4578 Cr | -32.4150 Cr | 9.6092 Cr | 20.1629 Cr | 0.0000 Cr | -8.2407 Cr |
| 2023-03-31 | 20.9101 Cr | -9.9240 Cr | -14.0687 Cr | 9.6298 Cr | -3.0826 Cr | 1.2795 Cr | -11.2803 Cr | 12.2797 Cr | -14.5686 Cr | 0.0000 Cr | -1.7585 Cr |
| 2022-03-31 | 8.5458 Cr | -16.4989 Cr | 12.1338 Cr | -9.2821 Cr | 4.1807 Cr | 4.3621 Cr | -17.8279 Cr | 12.2642 Cr | 3.4348 Cr | 0.0000 Cr | -9.1392 Cr |
| 2021-03-31 | 6.3089 Cr | -6.5649 Cr | 0.0506 Cr | -0.2312 Cr | -0.2054 Cr | 0.1814 Cr | -6.5401 Cr | -0.0837 Cr | 5.1316 Cr | 0.0000 Cr | 0.3619 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 49.04 Cr | 26.28 Cr | 22.76 Cr | 0.4641 | 4.80 Cr | 2.92 Cr | 2.56 | 7.06 Cr | 0.0595 |
| 2024-12-31 | 40.22 Cr | 21.56 Cr | 18.65 Cr | 0.4638 | 2.49 Cr | 1.21 Cr | 1.06 | 4.46 Cr | 0.0301 |
| 2024-09-30 | 48.36 Cr | 24.66 Cr | 23.71 Cr | 0.4902 | 5.31 Cr | 3.41 Cr | 2.97 | 8.19 Cr | 0.0705 |
| 2024-06-30 | 50.12 Cr | 31.75 Cr | 18.37 Cr | 0.3665 | 6.79 Cr | 3.98 Cr | 3.47 | 8.73 Cr | 0.0794 |
| 2024-03-31 | 46.37 Cr | 32.08 Cr | 14.29 Cr | 0.3081 | 4.04 Cr | 2.24 Cr | 1.95 | 5.96 Cr | 0.0483 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.55 Cr | 2.13 Cr | 2.68 Cr | 30.96 Cr | 25.77 Cr | 68.34 Cr | 109.44 Cr | 189.82 Cr | 106.58 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -79.10 Cr |
| 2024-09-30 | 0.18 Cr | 1.50 Cr | 1.68 Cr | 30.53 Cr | 21.63 Cr | 61.88 Cr | 105.54 Cr | 180.26 Cr | 101.16 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1.88 Cr | 0.00 Cr | 0.00 Cr | 1.88 Cr | 0.00 Cr | 0.00 Cr | -71.69 Cr |
| 2024-03-31 | 0.46 Cr | 1.42 Cr | 0.46 Cr | 32.56 Cr | 29.93 Cr | 75.43 Cr | 111.70 Cr | 188.77 Cr | 117.07 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 3.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 3.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 2.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 2.18 Cr | 3.56 Cr | 0.00 Cr | 0.00 Cr | 3.56 Cr | 4.45 Cr | 0.89 Cr | 0.00 Cr | 3.56 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹821.25 | ₹98,339,283,675.00 | ₹72,992.00 |
Key Executives
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Parnax Lab Limited
The CEO is Mihir Prakash Shah.
The current price is ₹122.50.
The range is ₹81-178.
The market capitalization is ₹140.70 crores.
The P/E ratio is 12.14.
The company operates in the Healthcare sector.
Overview of Parnax Lab Limited (ISIN: INE383L01019) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹140.70 crores and an average daily volume of 5,376 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.